During the transition period before prices decrease and positive economic effects are realized, the costs accruing to companies like Novo Nordisk and Eli Lilly are borne by payers, including corporations. This situation presents a negative factor for payers, affecting their financial burden and potentially influencing their decision-making processes.
The weight loss drug is so profitable that its parent company, Danish health care giant Novo Nordisk, is propping up Denmark’s entire economy. It’s poised to transform America’s too.
This episode was produced by Victoria Chamberlin edited by Jolie Myers, fact-checked by Kim Eggleston, engineered by Rob Byers, and hosted by Noel King.
Transcript at vox.com/todayexplained
Support Today, Explained by making a financial contribution to Vox! bit.ly/givepodcasts
Learn more about your ad choices. Visit podcastchoices.com/adchoices